(Q41864229)

13 October 2017

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis (English)

1 reference

13 October 2017

1 reference

Rafael Gálvez

1

1 reference

13 October 2017

Victoria Ribera

2

1 reference

13 October 2017

José Ramón González-Escalada

3

1 reference

13 October 2017

Alicia Souto

4

1 reference

13 October 2017

María Luz Cánovas

5

1 reference

13 October 2017

Andrés Castro

6

1 reference

13 October 2017

Begoña Herrero

7

1 reference

13 October 2017

María de Los Angeles Maqueda

8

1 reference

13 October 2017

Matilde Castilforte

9

1 reference

13 October 2017

José Javier Marco-Martínez

10

1 reference

13 October 2017

Concepción Pérez

11

1 reference

13 October 2017

Lorenza Vicente-Fatela

12

1 reference

13 October 2017

Consuelo Nieto Md

13

1 reference

13 October 2017

Maria José Orduña

14

1 reference

13 October 2017

Anna Padrol

15

1 reference

13 October 2017

Enrique Reig

16

1 reference

13 October 2017

Joaquín Carballido

17

1 reference

13 October 2017

José Manuel Cózar

18

1 reference

13 October 2017

language of work or name

English

0 references

publication date

2 February 2008

1 reference

Patient Preference and Adherence

13 October 2017

1 reference

13 October 2017

2

1 reference

13 October 2017

215-224

1 reference

Recommendations for zoledronic acid treatment of patients with bone metastases

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Assessment of therapeutic response in patients with metastatic bone disease

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Prostate carcinoma: defining therapeutic objectives and improving overall outcomes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Oral bisphosphonates: A review of clinical use in patients with bone metastases

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Managing breakthrough cancer pain: a new approach.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Overview of bisphosphonates

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Metastatic prostate cancer: assessment of response to systemic therapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Adverse effects of bisphosphonates. A comparative review

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Pain management in the patient with prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

New bisphosphonates in the treatment of bone metastases

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Etiology and current management of cancer-related hypercalcemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770417

[The therapeutic modalities of bone pain in prostate cancer]

18 August 2018

1 reference

12 December 2020

Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients

1 reference

12 December 2020

Osteoporosis after orchiectomy for prostate cancer

1 reference

12 December 2020

Morphometric evidence for bone resorption and replacement in prostate cancer

1 reference

12 December 2020

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

1 reference

12 December 2020

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

12 December 2020

Identifiers

DOI

10.2147/PPA.S2314

1 reference

13 October 2017

1 reference

13 October 2017

1 reference